@article{3128858,
    title = "Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The hellenic experience",
    author = "Siakantaris, M.P. and Tsirigotis, P. and Stavroyianni, N. and Argyropoulos, K.V. and Girkas, K. and Pappa, V. and Chondropoulos, S. and Papadavid, E. and Sakellari, I. and Anagnostopoulos, A. and Antoniou, C. and Dervenoulas, J.",
    journal = "Transfusion and Apheresis Science",
    year = "2012",
    volume = "46",
    number = "2",
    pages = "189-193",
    issn = "1473-0502",
    doi = "10.1016/j.transci.2011.10.029",
    keywords = "alpha interferon;  bexarotene;  denileukin diftitox;  pentostatin, adult;  aged;  article;  cancer survival;  clinical article;  clinical trial;  cutaneous T cell lymphoma;  extracorporeal photopheresis;  female;  follow up;  human;  male;  progression free survival;  PUVA;  survival time;  treatment outcome;  treatment response, Adult;  Aged;  Disease-Free Survival;  Female;  Follow-Up Studies;  Humans;  Immunologic Factors;  Lymphoma, T-Cell, Cutaneous;  Male;  Middle Aged;  Photopheresis;  Skin Neoplasms;  Survival Rate",
    abstract = "Extracorporeal photopheresis (ECP) is an established therapy for cutaneous T-cell lymphoma (CTCL). The objective of this study was to further explore the clinical efficacy of ECP combined with immunomodulatory agents.Eighteen patients with histologically proven CTCL were followed-up after therapy with ECP, mainly combined with interferon-α or bexarotene.A total of 61% of patients responded to therapy (n=11; CR: 5, PR: 6). Median survival was 51. months, progression free survival was 28. months and response duration was 29±23.9. months.ECP combined therapy was highly effective or had a palliative effect in CTCL resistant to previous treatments. © 2011."
}